RU2275200C2 - Pharmaceutical agent against animal eelworm - Google Patents

Abstract

FIELD: veterinary, in particular helminthology.

SUBSTANCE: claimed agent contains pyrantel, sodium ribonucleate, distilled water and target additive in ratio (mass pts) of 0.5-2.0:0.5:24:34.5, respectively. As target additive emulsifier and stabilizer are used. Pharmaceutical agent of present invention makes it possible to increase therapeutic effectiveness of pyrantel, to prevent eelworm reinvermination of animals, and to improve animal immune status.

EFFECT: drug against animal eelworm of improved effectiveness.

2 cl, 5 ex, 3 tbl

Description

The invention relates to the field of veterinary medicine, in particular to helminthology, and can be used to treat nematodoses of domestic and farm animals.

For the treatment of nematodoses, various salts of pyrantel are widely used (see, for example, Klenova I.O., Yaremenko N.A., Veterinary preparations in Russia, M., Selkhozizdat, 2000, p. 170-171, 180-181).

The closest drug is a suspension of pyrantel (see, for example, Belikov V.G., Synthetic and natural medicines, a quick reference, M., Higher School, 1993, p. 420-421). The drug is used in a dose of 15 mg / kg of animal weight.

The disadvantage of these drugs is that they do not prevent re-infection.

An object of the present invention is to provide a preparation having a prophylactic effect capable of preventing re-infection of animals with nematodes.

The problem is solved due to the fact that the preparation containing pyrantel and distilled water according to the invention additionally contains a sodium immunomodulator ribonucleate.

The preparation may contain a targeted additive, for example an emulsifier and a stabilizer.

It is advisable to use the following ratio of components in the preparation - pyrantel: sodium ribonucleate: target additive: distilled water - 1: 0.5: 24: 34.5.

The immunomodulator sodium ribonucleate (NaPHK) is known from the prior art and is used for the prevention and treatment of viral infections in animals and humans (see, for example, RU 2172631 C1, 08.27.2001).

The technical result provided by the invention is that the preparation improves the therapeutic efficacy of pyrantel, prevents re-infection of animals with nematodes, and improves the immune status of animals.

The invention is illustrated by the following examples, which, however, do not cover, and even more so do not limit the entire scope of the claims of this invention.

The drug is given the name "PIRADEK".

Example 1

To prepare a pyradec, 1 part of a pyrantel is taken, which is dissolved in 34.5 parts of water. Add the target additive (emulsifier and stabilizer) - 24 parts and 0.5 parts of the immunomonitor NaPHK.

An anthelmintic agent is prepared similarly to that described, in which the components are in the following proportions: pyrantel: sodium ribonucleate: target additive: water - 0.5: 0.5: 24: 34.5 and 2: 0.5: 24: 34.5.

Example 2

We took 15 dogs spontaneously infected with nematodes in the experiment, which were divided into 5 groups. The animals of the first group were given a “pyradec”, where the ratio of pyrantel: sodium ribonucleate: target additive: water is 1: 0.5: 24: 34.5; the animals of the second group were given a pyradec, in which the ratio was 0.5: 0.5: 24: 34.5; the animals of the third group were given a pyradec, in which the ratio was 2.0: 0.5: 24: 34.5; the fourth group was dehelmintized with pyrantel at a dose of 15 mg / kg; the fifth group served as control.

Intensity (IE) and prophylactic properties of the complex preparation were determined by the results of helminthological studies conducted 10 and 70 days after treatment. The results are shown in table 1.

Table 1.
The effectiveness of the proposed drug for toxocariasis and toxascaridosis of dogs No pp Preparations Ratio of components Intefficiency,% After 10 days After 70 days toxocaras goksaskarisy toxocaras toxaskaris one Pyradec 1: 0.5: 24: 34.5 one hundred one hundred one hundred one hundred 2 Pyradec 0.5: 0.5: 24: 34.5 92.4 88.2 24.6 16,2 3 Pyradec 2: 0.5: 24: 34.5 one hundred one hundred one hundred one hundred four Pyrantel 15 mg / kg 96.4 91.8 28.7 21,4 5 The control infected - - - -

Example 3

15 horses spontaneously infected with Oxyuris equi, Parascaris equorum, Strongylus equinus were taken into the experiment. The animals were divided into 3 groups: the first group received pyradec at a ratio of 1: 0.5: 24: 34.5 at a dose of 15 mg / kg in terms of DV, the second pyrantel at a dose of 15 mg / kg, and the third served as an infected control (table 2) . According to the results of helminthovoscopic studies, it was established: 100% IE in animals of the first group and 91.4-95.2% in the second group. In the study, after 70 days, the oxiuris eggs were found in the animals of the first group, and the oxiuris, parascaris and strongilat eggs were found in the second group, the animals of the third group remained infected.

Table 2.
The effectiveness of pyradec with horse nematodes Group No. A drug Dose Intensity% oxyuris parascaris strongilides one Pyradec 15 mg / kg 98.9 one hundred one hundred 2 Pyrantel 15 mg / kg 91.4 92.8 95.2 3 The control infected 0 0 0

Example 4

For the experiment, we took 12 calves spontaneously infected with strongilates of the gastrointestinal tract, and divided them into 3 groups: the first was de-helminthized with pyradec with a ratio of components of 1: 0.5: 24: 34.5; the second - pyrantel at the rate of 15 mg / kg, the third - control. After 10 days, a control helminthioscopic examination of feces was carried out. Set 100% IE in calves of the first group and 98.5% in the second group of calves.

Studies of feces from all experimental animals after 60 days showed that only single strongilat eggs were found in animals of the first group, 137 ± 21 eggs in 1 g of feces in the second group, animals of the control group were still infected and in 1 g of feces up to 153 ± 34 helminth eggs.

Example 5

Under the experiment they took 60 sheep spontaneously infected with strongylates. Animals were divided into 3 groups: the first was de-helminthized with pyradec, in which the ratio of components was 1: 0.5: 24: 34.5. The animals of the second group were dehelmintized with pyrantel at a dose of 15 mg / kg, animals of the 3rd group did not receive the drug and served as a control. During the experiment, the immune status was determined in animals and examined for re-infection.

An analysis of the results shows that pyradec containing components in a ratio of 1: 0.5: 24: 34.5 prevents the infection of sheep with strongilates for 60 days by 99.2%; pyrantel exempted sheep from invasion by 91.2%, and after 60 days, experimental animals of this group found eggs of strongilates in the amount of 264 ± 41 in 1 g of feces. In control animals in the dynamics of the study, the number of eggs of strongilates increased from 91.4 ± 27.2 to 257.8 ± 32 per 1 g of feces.

Indicators of the immune status of sheep are presented in table 3.

Table 3.
Immune status of sheep after deworming Indicators Groups of animals one 2 3 Before giving the drug T-lymphocytes,% 47.2 ± 2.4 46.6 ± 1.8 48.5 ± 1.2 T-helpers,% 6.8 ± 0.8 5.9 ± 0.2 5.7 ± 0.4 T-suppressors,% 14.6 ± 0.4 13.9 ± 0.9 14.2 ± 0.6 B-lymphocytes,% 28.8 ± 1.1 31.4 ± 0.9 27.8 ± 0.6 On the 10th day T-lymphocytes,% 50.2 ± 2.7 39.4 ± 2.2 40.4 ± 2.7 T-helpers,% 12.8 ± 0.9 5.7 ± 0.2 5.8 ± 0.2 T-suppressors,% 4.4 ± 0.7 19.8 ± 0.4 20.4 ± 0.4 B-lymphocytes,% 32.4 ± 1.1 30.8 ± 0.9 26.8 ± 0.9 On the 70th day T-lymphocytes,% 48.4 ± 3.1 37.8 ± 1.9 38.9 ± 2.7 T-helpers,% 11.2 ± 0.9 6.6 ± 0.4 6.6 ± 0.2 T-suppressors,% 5.2 ± 0.1 18.7 ± 0.7 19.2 ± 0.4 B-lymphocytes,% 34.7 ± 2.8 32.2 ± 0.4 29.4 ± 1.4

The results show that the introduction of the complex drug pyradec releases animals from nematodes and prevents nematodoses for 60 days, and also increases the immune status of animals.

Claims (2)

1. The drug against nematodoses of animals, containing pyrantel and distilled water, characterized in that it additionally contains sodium ribonucleate and the target additive, in the following ratio of components, parts by weight: pyrantel: sodium ribonucleate: target additive: distilled water = 0.5- 2.0: 0.5: 24: 34.5. 2. The drug according to claim 1, characterized in that as the target additive contains an emulsifier and a stabilizer.